peterschreiber.media
BofA has initiated coverage of Candel Therapeutics (NASDAQ:CADL) with a buy rating, citing the potential of its immunotherapy drug candidates CAN-2409 and CAN-3110.
“While approved therapies may have more historical precedent for efficacy/success, we see the ability to turn immunologically unresponsive ‘cold’ tumors ‘hot’ and